Showing 20 of 31 recruiting trials for “mild-hemophilia-b”
SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis
PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A）
RecruitingNCT07101926 ↗
Monitoring of Anti-TFPI in Hemophilia
Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy
RecruitingNCT07314983 ↗
Long-term Anticoagulation in a Patient With Severe Hemophilia A
Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa
A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.
To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
Manual Therapy in Hemophilic Arthropathy of the Ankle
An Open-Label, Comparative Study of the Efficacy, Safety and Pharmacodynamics of Single Dose of ANB-002 in Patients With Hemophilia B
Measurement Properties in People with Hemophilia
Enrolling by InvitationNCT06826209 ↗
Comparison of Upper Extremity Functional Performance in Hemophilic and Healthy Children
A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
Effectiveness of an Adapted Physical Activity Program for Subjects Suffering From Haemophilia
Feasibility and Safety of Blood-Flow-Restriction Training in Patients With Hemophilia
Efficacy and Safety Evaluation Study of SCT800 in Previously Untreated Hemophilia A Patients.
A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab
Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study
👨⚕️ Shveta Gupta, MD, Arnold Palmer Hospital for Children📍 18 sites📅 Started Nov 2023View details ↗
ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor
👨⚕️ Lei Zhang, Chinese Academy of Medical Science and Blood Disease Hospital📍 1 site📅 Started Nov 2023View details ↗
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
Page 1 of 2Next →
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →